Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response

Study acronym: EASY
StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion moved earlier from Jul 7, 2029 to Apr 13, 2029
    • Start date changed from estimate of Jul 7, 2026 to Apr 13, 2026
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 4 of 5 entries
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date: May 1, 2025 to Jul 7, 2026
    • Primary and study completion dates: May 1, 2029 to Jul 7, 2029
    • Site details revised
    v4
  3. Re-verified, no change to tracked fieldsv3
  4. Phase: Phase 1 to Not applicable
    • Secondary endpoints: details revised at 4 of 5 entries
    v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This prospective, single-arm feasibility study will include patients with prostate cancer that have controlled local disease diagnosed with oligorecurrent para-aortic nodal disease and/or common iliac nodal disease detected by PSMA PET or conventional CT/MRI imaging, and these patients will undergo CT-guided online adaptive SBRT to the tumor and elective SBRT to adjacent at-risk nodal regions.
Trial Details
NCT Number NCT06831032
Lead Sponsor University Health Network, Toronto
Conditions
(from sponsor)		 Prostate Adenocarcinoma, Iliac Nodal Disease, Para-aortic Lymph Node Metastasis, Para-aortic Nodal Disease, Oligorecurrence
Enrollment 26 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov